Rational development of molecularly imprinted nanoparticles for blocking PD-1/PD-L1 axis

• DOI: 10.1039/d2sc03412c
• Publication Date: 2022-08-30T13:00:48Z
• Authors: Zikuan Gu; Shuxin Xu; Zhanchen Guo; Zhen Liu
• Keywords: Blocking (statistics); Molecularly imprinted polymer; Cancer Immunotherapy; Blocking antibody; Immune checkpoint

Blocking the PD-1/PD-L1 immune checkpoint has emerged as a promising strategy in cancer immunotherapy, which monoclonal antibodies are predominately used inhibitors. Despite their remarkable success, antibody-based therapeutics suffer from drawbacks due to use of antibodies, such high cost, low stability and frequency immune-related adverse effects. Therefore, novel anti-PD-1/PD-L1 that can address these issues significant importance. Herein, we report molecularly imprinted polymer (MIP) based PD-1 nano inhibitor for blocking axis. The anti-PD-1 nanoMIP was rationally designed engineered by epitope imprinting using N-terminal binding site. showed good specificity affinity towards PD-1, yielding disassociation constant at 10